Krystal Biotech, Inc. — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
KRYS
Krystal Biotech, Inc. · Biotechnology
FCF$237mC
Rev+25.1%A-
D/E0.01A
P/E49.0xC
PEG1.44B
70.8Score
$365.81$10.8B
1Y Target$349.78Analyst consensus · 9 analysts
5Y Target$512.11Compound horizon
10Y Target$759.68Long-dated conviction
FCF$237mTTMC
FCF $237m — modest; watch for margin expansion
Rev+25.1%TTM YoYA-
Revenue +25.1% — strong growth, well above S&P median (~7%)
D/E0.01A
D/E 0.01 — least levered decile in Healthcare (≈10th pctile)
P/E49.0xC
P/E 49.0 — expensive vs Healthcare peers (≈90th pctile)
PEG1.44proxyB
PEG 1.44 — acceptable premium for growth · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 70.8
Quality0.71
Growth1.00
Value0.50
Entry · Margin of safety
52-week rangeNear 52-week high
4% off the 12-month high
vs DCF fair value108% aboveest. fair value ~$176
What the price assumes: free cash flow compounding at ~32% a year for the next decade — vs the ~21% a year our model projects from current growth and analyst estimates.
Quality signals · context only
ROIC11.0% · Breturn on invested capital — not score-weighted
Why now
Biotechnology · market cap $10.8b. 4% off the 52-week high of $382.54. Revenue growing +25% — in hypergrowth territory. 9 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $349.78 (implying -4% upside).
Moat
Net margin 54% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 105% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 49x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 25.8x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Horizon
1-3 yr $349.78 (9-analyst consensus) — fundamentals + valuation re-rating. 5 yr $512.11 at ~7% CAGR — compounding case rests on the competitive position widening. 10 yr $759.68 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · KRYS
Trend
+6.6 over 15 daily scores
From 64.2 (Jun 22) → 70.8 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · KRYS
$
%
%
Shares to buy
5
Position size
$1,829
3.7% of portfolio
Stop price
$274.36
25% below $365.81
$ at risk if stopped
$457.26
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Krystal Biotech, Inc. (KRYS): score, valuation & FAQ
Krystal Biotech, Inc. (KRYS) is a Biotechnology company that scores 70.8 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A) and Rev (A-). On valuation, KRYS sits about 108% above our discounted-cash-flow fair value — the current price implies roughly 32% annual free-cash-flow growth over the next decade.
Is KRYS a good stock to buy?
Bull Rankings scores KRYS 70.8 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by D/E (A) and Rev (A-). A score is a quantitative screen of Krystal Biotech, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does KRYS score 70.8 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). KRYS earns its highest marks on D/E (A) and Rev (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is KRYS overvalued or undervalued?
Based on $365.81, KRYS sits about 108% above our discounted-cash-flow fair value — the current price implies roughly 32% annual free-cash-flow growth over the next decade. It trades at a 49.0x× P/E (graded C). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in KRYS?
Trailing P/E 49x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 25.8x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.